Regenerative Medicine in Orthopaedics: An Evidence-Based Optimism

The fundamental premise of regenerative medicine — that stimulating and supporting the body's intrinsic healing capacity can produce better tissue restoration than purely mechanical or pharmacological approaches — addresses a genuine limitation of conventional orthopaedic management. Tendons, cartilage, and certain bone conditions have inherently limited healing capacity: poor vascularity, low cell turnover, and the biomechanical environment of the musculoskeletal system make sustained, complete healing difficult without biological support. Regenerative approaches are designed to address exactly these limitations.

Platelet-rich plasma: where the evidence is strongest

Platelet-rich plasma — a concentration of the patient's own platelets and their associated growth factors, prepared from an autologous blood draw and delivered to the target tissue — has the longest clinical track record in regenerative orthopaedics and the most substantial evidence base. For lateral epicondylalgia refractory to physiotherapy, PRP produces better outcomes than corticosteroid injection at two-year follow-up in multiple well-conducted trials. The biological rationale is directly linked to the pathology: delivering growth factors to a tissue characterised by failed healing stimulates the collagen synthesis and maturation that conventional treatments do not address.

For early-stage osteoarthritis — where PRP is increasingly used as a viscosupplementation alternative — the evidence is more mixed but broadly supportive in younger patients with less advanced disease. For rotator cuff augmentation — applied at the repair site during surgical reconstruction to support tendon-to-bone healing — early results are promising, particularly in at-risk repairs in older patients or those with compromised tendon quality.

Bone marrow aspirate concentrate and cellular therapies

Bone marrow aspirate concentrate — which contains mesenchymal stem cells, haematopoietic progenitor cells, and multiple growth factors — represents a more complex regenerative preparation with applications across cartilage repair, bone healing augmentation, and tendon pathology. The evidence base is earlier stage than for PRP but growing, with several well-designed trials demonstrating meaningful clinical benefit in specific indications. My own edited textbook on this subject documents the clinical applications and evidence across the range of musculoskeletal conditions where these treatments are being investigated.

The critical principle — the one that distinguishes evidence-based regenerative practice from the unfortunately prevalent commercialised overselling of unproven treatments — is indication precision. Regenerative treatments have documented benefit in specific conditions, at specific stages of disease, in specifically selected patients. Offering them as universal solutions for all musculoskeletal complaints, at significant cost and without the evidence base to support the indication, is an ethical failure that the clinical community has both the responsibility and the capability to address.